These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23792349)

  • 1. Ligand/kappa-opioid receptor interactions: insights from the X-ray crystal structure.
    Martinez-Mayorga K; Byler KG; Yongye AB; Giulianotti MA; Dooley CT; Houghten RA
    Eur J Med Chem; 2013 Aug; 66():114-21. PubMed ID: 23792349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of the human κ-opioid receptor in complex with JDTic.
    Wu H; Wacker D; Mileni M; Katritch V; Han GW; Vardy E; Liu W; Thompson AA; Huang XP; Carroll FI; Mascarella SW; Westkaemper RB; Mosier PD; Roth BL; Cherezov V; Stevens RC
    Nature; 2012 Mar; 485(7398):327-32. PubMed ID: 22437504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidation of conformational states, dynamics, and mechanism of binding in human κ-opioid receptor complexes.
    Leonis G; Avramopoulos A; Salmas RE; Durdagi S; Yurtsever M; Papadopoulos MG
    J Chem Inf Model; 2014 Aug; 54(8):2294-308. PubMed ID: 25060329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa-opioid receptor.
    Przydzial MJ; Pogozheva ID; Bosse KE; Andrews SM; Tharp TA; Traynor JR; Mosberg HI
    J Pept Res; 2005 Mar; 65(3):333-42. PubMed ID: 15787963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docking and free energy perturbation studies of ligand binding in the kappa opioid receptor.
    Goldfeld DA; Murphy R; Kim B; Wang L; Beuming T; Abel R; Friesner RA
    J Phys Chem B; 2015 Jan; 119(3):824-35. PubMed ID: 25395044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.
    Carroll I; Thomas JB; Dykstra LA; Granger AL; Allen RM; Howard JL; Pollard GT; Aceto MD; Harris LS
    Eur J Pharmacol; 2004 Oct; 501(1-3):111-9. PubMed ID: 15464069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of the 3- and 4-methyl substituents.
    Carroll FI; Gichinga MG; Kormos CM; Maitra R; Runyon SP; Thomas JB; Mascarella SW; Decker AM; Navarro HA
    Bioorg Med Chem; 2015 Oct; 23(19):6379-88. PubMed ID: 26342544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanobody-enabled monitoring of kappa opioid receptor states.
    Che T; English J; Krumm BE; Kim K; Pardon E; Olsen RHJ; Wang S; Zhang S; Diberto JF; Sciaky N; Carroll FI; Steyaert J; Wacker D; Roth BL
    Nat Commun; 2020 Mar; 11(1):1145. PubMed ID: 32123179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).
    Cai TB; Zou Z; Thomas JB; Brieaddy L; Navarro HA; Carroll FI
    J Med Chem; 2008 Mar; 51(6):1849-60. PubMed ID: 18307295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
    Thomas JB; Atkinson RN; Vinson NA; Catanzaro JL; Perretta CL; Fix SE; Mascarella SW; Rothman RB; Xu H; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 2003 Jul; 46(14):3127-37. PubMed ID: 12825951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the structure of opioid receptors with homology modeling based on single and multiple templates and subsequent docking: a comparative study.
    Bera I; Laskar A; Ghoshal N
    J Mol Model; 2011 May; 17(5):1207-21. PubMed ID: 20661609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective κ opioid antagonists nor-BNI, GNTI and JDTic have low affinities for non-opioid receptors and transporters.
    Munro TA; Huang XP; Inglese C; Perrone MG; Van't Veer A; Carroll FI; Béguin C; Carlezon WA; Colabufo NA; Cohen BM; Roth BL
    PLoS One; 2013; 8(8):e70701. PubMed ID: 23976952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.
    Subramanian G; Paterlini MG; Larson DL; Portoghese PS; Ferguson DM
    J Med Chem; 1998 Nov; 41(24):4777-89. PubMed ID: 9822548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicted structures for kappa opioid G-protein coupled receptor bound to selective agonists.
    Li Q; Kim SK; Goddard WA; Chen G; Tan H
    J Chem Inf Model; 2015 Mar; 55(3):614-27. PubMed ID: 25642595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints.
    Pogozheva ID; Lomize AL; Mosberg HI
    Biophys J; 1998 Aug; 75(2):612-34. PubMed ID: 9675164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational insights into the subtype selectivity and "message-address-efficacy" mechanisms of opioid receptors through JDTic binding and unbinding.
    Cheng JX; Cheng T; Li WH; Liu GX; Zhu WL; Tang Y
    Acta Pharmacol Sin; 2018 Mar; 39(3):482-491. PubMed ID: 29047460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of (3R)-1,2,3,4-tetrahydro-7-hydroxy-N-[(1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-isoquinolinecarboxamide (JDTic) analogues: in vitro pharmacology and ADME profile.
    Kormos CM; Gichinga MG; Maitra R; Runyon SP; Thomas JB; Brieaddy LE; Mascarella SW; Navarro HA; Carroll FI
    J Med Chem; 2014 Sep; 57(17):7367-81. PubMed ID: 25133923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel fluoroalkyl derivatives of selective kappa opioid receptor antagonist JDTic: Design, synthesis, pharmacology and molecular modeling studies.
    Schmitt S; Colloc'h N; Perrio C
    Eur J Med Chem; 2015 Jan; 90():742-50. PubMed ID: 25513968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotype-selective modes of action of κ-opioid receptor agonists.
    Vardy E; Mosier PD; Frankowski KJ; Wu H; Katritch V; Westkaemper RB; Aubé J; Stevens RC; Roth BL
    J Biol Chem; 2013 Nov; 288(48):34470-83. PubMed ID: 24121503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic Relationships between Duration of Action of JDTic-like Kappa-Opioid Receptor Antagonists and Their Brain and Plasma Pharmacokinetics in Rats.
    Owens SM; Pollard GT; Howard JL; Fennell TR; Snyder RW; Carroll FI
    ACS Chem Neurosci; 2016 Dec; 7(12):1737-1745. PubMed ID: 27700049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.